Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: Deconstructing a myth?

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 563-565

  Barosi, Giovanni ^a   Gale, Robert Peter ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Clonality; Fibroblasts; MPN; Myelofibrosis

Indexed keywords

GLUCOSE 6 PHOSPHATE; JANUS KINASE; TRANSFORMING GROWTH FACTOR BETA;

BONE MARROW BIOPSY; CELL CULTURE; CLONAL VARIATION; CYTOGENETICS; ENDOTHELIUM CELL; FIBROBLAST; GENE MUTATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HETEROZYGOSITY; HUMAN; LETTER; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

CLONE CELLS; CONCEPT FORMATION; CYTOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYELOPROLIFERATIVE DISORDERS; MYTHOLOGY; NEOPLASMS; PRIMARY MYELOFIBROSIS;

EID: 79954625832     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.013     Document Type: Letter

References (30)

1. Mesa R.A., Green A., Barosi G., Verstovsek S., Vardiman J., Gale R.P. MPN-associated myelofibrosis (MPN-MF). Leuk Res 2011, 35:12-13.
2. Castro-Malaspina H., Jhanwar S.C. Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res 1984, 154:307-322.
3. Le Bousse-Kerdilès M.C., Martyré M.C., Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 2008, 19:69-80.
4. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005, 23:8520-8530.
5. Silver R.T., Vandris K. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukemia 2009, 23:1366-1369.
6. Tefferi A., Cortes J., Verstovsek S., Mesa R.A., Thomas D., Lasho T.L., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158-1164.
7. Thomas D.A., Giles F.J., Albitar M., Cortes J.E., Verstovsek S., Faderl S., et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006, 106:1974-1984.
8. Castro-Malaspina H., Gay R.E., Jhanwar S.C., Hamilton J.A., Chiarieri D.R., Meyers P.A., et al. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. Blood 1982, 59:1046-1054.
9. Nowell P.C., Finan J.B. Cytogenetics of acute and chronic myelofibrosis. Virchows Arch Cell Pathol 1978, 29:45-50.
10. Greenberg B.R., Woo L., Veomett I.C., Payne C.M., Ahmann F.R. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br J Haematol 1987, 66:487-490.
11. Jacobson R.J., Salo A., Fialkow P.J. Agnogenic myeloid metapalsia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978, 51:189-194.
12. Bacher U., Asenova S., Badbaran A., Zander A.R., Alchalby H., Fehse B., et al. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. Clin Exp Med 2010, 10:205-208.
13. Mercier F., Monczak Y., François M., Prchal J., Galipeau J. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. Exp Hematol 2009, 37:416-420.
14. Pieri L., Guglielmelli P., Bogani C., Bosi A., Vannucchi A.M. Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leuk Res 2008, 32:516-517.
15. Rosti V., Bonetti E., Villani L., Primignani M., Bergamaschi G., Massa M., et al. Circulating endothelial colony-forming cells are increased in patients with primary myelofibrosis, do not bear the JAK2-V617F mutation, and coexist with JAK2 V617F positive mature endothelial cells. Haematologica 2009, 94(Suppl. 2). 351 abs. 0872.
16. Sozer S., Fiel M.I., Schiano T., Xu M., Mascarenhas J., Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009, 113:5246-5249.
17. Yoder M.C., Mead L.E., Prater D., Krier T.R., Mroueh K.N., Li F., Krasich R., Temm C.J., Prchal J.T., Ingram D.A. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
18. Teofili L., Martini M., Iachininoto M.G., Capodimonti S., Nuzzolo E.R., Torti L., et al. Endothelial progenitor cells are clonal and exhibit JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 2011, (January). [Epub ahead of print].
19. Boveri E., Passamonti F., Rumi E., Pietra D., Elena C., Arcaini L., et al. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 2008, 140:162-168.
20. Arora B., Ho C.L., Hoyer J.D., Mesa R.A., Tefferi A. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica 2004, 89:1454-1458.
21. Ni H., Barosi G., Hoffman R. Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol 2006, 126:241-247.
22. Zetterberg E., Vannucchi A.M., Migliaccio A.R., Vainchenker W., Tulliez M., Dickie R., et al. Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica 2007, 92:597-604.
23. Rajkumar V.S., Howell K., Csiszar K., Denton C.P., Black C.M., Abraham D.J. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005, 7:R1113-R1123.
24. Katsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2010, (January). [Epub ahead of print].
25. Achille V., Novara F., Mantelli M., Avanzini M.A., Rosti V., Maccario R., et al. In vitro expanded MCSs from patients with myeloproliferative neoplasms at late passages show recurrent cytogentic abnornalities. Blood 2010, 116:1669. abstract no. 4101.
26. Vannucchi A.M., Bianchi L., Paoletti F., Pancrazzi A., Torre E., Nishikawa M., et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 2005, 105:3493-3501.
27. Schmitt A., Jouault H., Guichard J., Wendling F., Drouin A., Cramer E.M. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000, 96:1342-1347.
28. Bock O., Loch G., Schade U., von Wasielewski R., Schlué J., Kreipe H. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol 2005, 205:548-557.
29. Campanelli R., Rosti V., Villani L., Castagno M., Moretti E., Bonetti E., et al. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. Cytokine 2011, 53:100-106.
30. Kralovics R., Teo S.S., Li S., Theocharides A., Buser A.S., Tichelli A., et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006, 108:1377-1380.